Market Overview
Nuclear medicine equipment includes single-photon emission computed tomography (SPECT), positron emission tomography (PET), and hybrid systems such as SPECT/CT and PET/MRI that combine anatomical and functional imaging. These tools are used primarily in oncology, cardiology, neurology, and other clinical specialties to diagnose and stage disease, guide treatment planning, and monitor therapeutic response.
- •The market was valued at approximately $6.01 billion in 2025, with projections varying across research firms based on differing scope and methodology
- •Forecasts suggest the market could reach roughly $8.3 billion by 2030 under moderate growth assumptions
- •Equipment is broadly categorized into SPECT systems, PET systems, and hybrid imaging platforms, with hybrid systems gaining share due to superior diagnostic accuracy
Growth Drivers
The rising global burden of chronic diseases, particularly cancer and cardiovascular conditions, is a primary driver of demand for nuclear medicine imaging. An aging population in developed and emerging economies alike increases the incidence of conditions requiring nuclear imaging for diagnosis and management.
- •Increasing prevalence of cancer and cardiovascular diseases fuels demand for early, accurate diagnostic imaging
- •Technological advancements in hybrid imaging systems, software-based image reconstruction, and new radiopharmaceuticals improve clinical utility and adoption
- •Growing healthcare infrastructure investment in emerging markets expands access to advanced diagnostic capabilities
Segmentation and Regional Analysis
The market is segmented by product type into SPECT, PET, and hybrid systems, with additional segmentation by application, end user such as hospitals and diagnostic imaging centers, and geography. North America historically leads due to advanced healthcare infrastructure, high adoption of innovative imaging technologies, and favorable reimbursement frameworks, while the Asia-Pacific region is expected to see the fastest growth.
- •North America holds the largest market share, supported by high healthcare spending and early adoption of advanced imaging technologies
- •Asia-Pacific is projected to be the fastest-growing region, driven by rising healthcare access, medical tourism, and increasing prevalence of chronic diseases
- •Europe represents a significant and mature market, with steady growth driven by aging demographics and continued investment in diagnostic imaging infrastructure
Trends and Outlook
What are the recent trends and outlook?
Key trends shaping the market include the growing adoption of theranostics, which combines diagnostic imaging with targeted radionuclide therapy, and the integration of artificial intelligence into image analysis and workflow optimization. Supply chain considerations for radiopharmaceuticals, particularly molybdenum-99, continue to influence market dynamics.
- •Theranostics is emerging as a significant trend, bridging diagnostic nuclear medicine with personalized radionuclide therapies, especially in oncology
- •Artificial intelligence and machine learning are being integrated into nuclear imaging systems to enhance image quality, reduce scan times, and improve diagnostic accuracy
- •The development of novel radiopharmaceuticals, including targeted therapies for prostate and neuroendocrine tumors, is expected to expand the clinical indications for nuclear medicine
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.